BDBM230107 US10106559, Example 33::US10435415, Example 33::US9334290, 32::US9850258, Example 33

SMILES Cc1c(cccc1-n1c(=O)cc2c(Cl)cccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O

InChI Key InChIKey=IRBVGTPPFBYDKX-UHFFFAOYSA-N

Data  50 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 50 hits for monomerid = 230107   

TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of JAK2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.20E+4nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetCytochrome P450 2B6(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.20E+4nMAssay Description:Inhibition of CYP2B6 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.20E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.20E+4nMAssay Description:Inhibition of CYP2C19 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C8(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 3.20E+3nMAssay Description:Inhibition of CYP2C8 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 5.70E+3nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.10E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1nMAssay Description:Inhibition of BTK in human peripheral B cells assessed as reduction in anti-IgM/IgG-induced CD86 surface expressionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of BTK in human peripheral B cells assessed as reduction in CD40/CD40L-induced CD86 surface expressionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 2nMAssay Description:Inhibition of BTK in human PBMC cells assessed as inhibition of FCepsilonR1/immune complex-induced TNFalpha productionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Mouse)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 130nMAssay Description:Inhibition of BTK in mouse whole blood assessed as reduction in anti-IgM/IgG-induced CD69 surface expression on peripheral B cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 54nMAssay Description:Inhibition of BTK in human whole blood assessed as reduction in FCepsilonR1/anti-IgE-induced CD63 surface expression on basophilsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human ERG by patch clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of JAK2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 180nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 180nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 0.550nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 17nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 300nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 10nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 10nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 87nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 162nMAssay Description:Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 162nMAssay Description:Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 970nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.40E+3nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 0.550nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.40E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 0.260nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 970nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 0.480nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 760nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 0.330nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.70E+3nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 0.550nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.40E+3nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 0.260nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 0.550nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 0.550nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 1.40E+3nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 0.260nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 970nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Tec(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 3nMAssay Description:Inhibition of TEC (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 5nMAssay Description:Inhibition of BLK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 7nMAssay Description:Inhibition of BMX (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase TXK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 10nMAssay Description:Inhibition of TXK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase Fgr(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 15nMAssay Description:Inhibition of FGR (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase Yes(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 19nMAssay Description:Inhibition of YES1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase ITK/TSK(Human)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 21nMAssay Description:Inhibition of ITK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed